Resolution of the Council of Experts “The role of the drug rurioctocog alfa pegol in the treatment of patients with hemophilia A”

1. Instructions for medical use of the drug Adenovate®. [Electronic resource]: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=45878db3-0e74-4584-9bdd-d772e10a5557&t= (appeal date 07.09.2021). (In Russ.).

2. Konkle B.A., Stasyshyn O., Chowdary P., Bevan D.H., Mant T., Shima M., Engl W., Dyck-Jones J., Fuerlinger M., Patrone L., Ewenstein B., Abbuehl B. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078–85. doi:10.1182/blood-2015-03-630897.

3. Mullins E.S., Stasyshyn O., Alvarez-Roman M.T., Osman D., Liesner R., Engl W., Sharkhawy M., Abbuehl B.E. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017;23(2):238–46. doi:10.1111/hae.13119.

4. Booth J. et al. EAHAD, Paris, France, 2017; Poster P078.

5. Chowdary P., Mullins E.S., Konkle B.A., McGuinn C., Park Y.S., Stasyshyn O., Zulfikar B., Engl W., Tangada S. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia. 2020;26:e168–e78. doi:10.1111/hae.14052.

6. Klamroth R., Windyga J., Radulescu V., Collins P.W., Stasyshyn O., Ibrahim H.M., Engl W., Tangada S.D., Savage W., Ewenstein B. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. Blood. 2021;137(13):1818–27. doi:10.1182/blood.2020005673.